Key trends emerging in the Ixchiq market include the development of a chikungunya vaccine. A notable instance is Valneva SE, a France-based biotechnology company, who received marketing ...

In November, the U.S. FDA approved Ixchiq as the world’s first chikungunya vaccine. The company reported 28-day and six-month data from the VLA1553-321 trial in 2023 and 2024, respectively.

The vaccine, Ixchiq, is already approved in the US, Europe and Canada to prevent the mosquito-borne viral disease in individuals aged 18 years and older. Valneva said the updated results from the ...

to expand the use of Ixchiq to patients aged 12 to 17, and now plans to do the same in the UK. This development comes a week after Bavarian Nordic’s vaccine Vimkunya moved closer to the European ...

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.) 2, Europe 3 and Canada ...

(RTTNews) - Valneva SE (VALN) a specialty vaccine company, on Wednesday announced that it is advancing to a Phase 3 trial for IXCHIQ, its single-dose chikungunya vaccine, in children aged 1 to 11 ...

Valneva entered a partnership with CEPI in 2019, with support from the European Union (EU) Horizon program, to support late-stage development of Ixchiq and expand access to the vaccine for at-risk ...

Valneva (NASDAQ:VALN) ADRs traded higher in the premarket on Tuesday after the French biotech posted additional data for its FDA-approved chikungunya vaccine, Ixchiq, from a Phase 3 trial for ...

Valneva submitted label extension applications to the U.S. Food and Drug Administration FDA , the European Medicines Agency EMA and Health Canada to potentially extend the use of IXCHIQ to ...